Cover Image
市場調查報告書

Alba Therapeutics Corporation.:產品平台分析

Alba Therapeutics Corporation - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 251741
出版日期 內容資訊 英文 28 Pages
訂單完成後即時交付
價格
Back to Top
Alba Therapeutics Corporation.:產品平台分析 Alba Therapeutics Corporation - Product Pipeline Review - 2015
出版日期: 2015年05月13日 內容資訊: 英文 28 Pages
簡介

Alba Therapeutics Corporation是主要以自體免疫疾病及發炎性疾病之治療藥的研發、產品化之生物製藥公司。該公司的技術平台活用調整細胞間分子的流程來治療自體免疫疾病及發炎疾病。此外也提供腸胃、代謝、肺、腎臟等分類為各種免疫基礎的疾病治療藥。

本報告提供Alba Therapeutics Corporation的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,以及後期階段及中止的計劃等相關資訊。

Alba Therapeutics Corporation的基本資料

  • Alba Therapeutics Corporation概要
  • 主要資訊
  • 企業資料

Alba Therapeutics Corporation:R&D概要

  • 主要的治療範圍

Alba Therapeutics Corporation:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Alba Therapeutics Corporation:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Alba Therapeutics Corporation:藥物簡介

  • larazotide acetate
  • AT-1004
  • AT-1006
  • AT-1005
  • Drug 1 to Inhibit Permeability for Autoimmune Disorders and Inflammation
  • Drug 2 to Inhibit Permeability for Autoimmune Disorders and Inflammation

Alba Therapeutics Corporation:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Alba Therapeutics Corporation:最近的開發平台趨勢

Alba Therapeutics Corporation:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07069CDB

Summary

Global Markets Direct's, 'Alba Therapeutics Corporation - Product Pipeline Review - 2015', provides an overview of the Alba Therapeutics Corporation's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Alba Therapeutics Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Alba Therapeutics Corporation including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Alba Therapeutics Corporation's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Alba Therapeutics Corporation's pipeline products

Reasons to buy

  • Evaluate Alba Therapeutics Corporation's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Alba Therapeutics Corporation in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Alba Therapeutics Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Alba Therapeutics Corporation and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Alba Therapeutics Corporation
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Alba Therapeutics Corporation and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Alba Therapeutics Corporation Snapshot
    • Alba Therapeutics Corporation Overview
    • Key Information
    • Key Facts
  • Alba Therapeutics Corporation - Research and Development Overview
    • Key Therapeutic Areas
  • Alba Therapeutics Corporation - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Alba Therapeutics Corporation - Pipeline Products Glance
    • Alba Therapeutics Corporation - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Alba Therapeutics Corporation - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Alba Therapeutics Corporation - Drug Profiles
    • larazotide acetate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AT-1004
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AT-1006
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AT-1005
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs to Induce Permeability for Autoimmune Disorders and Inflammation
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs to Inhibit Permeability for Autoimmune Disorders and Inflammation
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Alba Therapeutics Corporation - Pipeline Analysis
    • Alba Therapeutics Corporation - Pipeline Products by Target
    • Alba Therapeutics Corporation - Pipeline Products by Route of Administration
    • Alba Therapeutics Corporation - Pipeline Products by Molecule Type
    • Alba Therapeutics Corporation - Pipeline Products by Mechanism of Action
  • Alba Therapeutics Corporation - Recent Pipeline Updates
  • Alba Therapeutics Corporation - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Alba Therapeutics Corporation, Key Information
  • Alba Therapeutics Corporation, Key Facts
  • Alba Therapeutics Corporation - Pipeline by Indication, 2015
  • Alba Therapeutics Corporation - Pipeline by Stage of Development, 2015
  • Alba Therapeutics Corporation - Monotherapy Products in Pipeline, 2015
  • Alba Therapeutics Corporation - Phase II, 2015
  • Alba Therapeutics Corporation - Phase I, 2015
  • Alba Therapeutics Corporation - Preclinical, 2015
  • Alba Therapeutics Corporation - Discovery, 2015
  • Alba Therapeutics Corporation - Pipeline by Target, 2015
  • Alba Therapeutics Corporation - Pipeline by Route of Administration, 2015
  • Alba Therapeutics Corporation - Pipeline by Molecule Type, 2015
  • Alba Therapeutics Corporation - Pipeline Products by Mechanism of Action, 2015
  • Alba Therapeutics Corporation - Recent Pipeline Updates, 2015

List of Figures

  • Alba Therapeutics Corporation - Pipeline by Top 10 Indication, 2015
  • Alba Therapeutics Corporation - Pipeline by Stage of Development, 2015
  • Alba Therapeutics Corporation - Monotherapy Products in Pipeline, 2015
  • Alba Therapeutics Corporation - Pipeline by Top 10 Target, 2015
  • Alba Therapeutics Corporation - Pipeline by Top 10 Route of Administration, 2015
  • Alba Therapeutics Corporation - Pipeline by Top 10 Molecule Type, 2015
  • Alba Therapeutics Corporation - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top